Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nutrition & Metabolism
Published in: Nutrition & Metabolism 1/2013

Open Access 01-12-2013 | Research

Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice

Authors: Zhi-Hong Yang, Hiroko Miyahara, Yusuke Iwasaki, Jiro Takeo, Masashi Katayama

Published in: Nutrition & Metabolism | Issue 1/2013

Login to get access

Abstract

The objective of present study was to examine the effect of long-chain monounsaturated fatty acids (LC-MUFAs) with chain lengths longer than 18 (i.e., C20:1 and C22:1 isomers combined) on obesity-related metabolic dysfunction and its molecular mechanisms. Type-2 diabetic KK-Ay mice (n = 20) were randomly assigned to the 7% soybean oil-diet group (control group) and 4% LC-MUFA concentrate-supplemented-diet group (LC-MUFA group). At 8 weeks on the diet, the results showed that plasma, liver and adipose tissue levels of C20:1 and C22:1 isomers increased significantly with LC-MUFA treatment. Supplementation with LC-MUFAs markedly reduced white fat pad weight as well as adipocyte size in the mice. The levels of plasma free fatty acids, insulin, and leptin concentration in the obese diabetic mice of the LC-MUFA group were also decreased as compared with the mice in the soybean oil-diet control group. Dietary LC-MUFAs significantly increased the mRNA expression of peroxisome proliferator-activated receptor gamma (Pparg), lipoprotein lipase (Lpl), fatty acid transport protein (Fatp), fatty acid translocase/CD36 (Cd36), as well as mRNA expression of genes involved in lipid oxidation such as carnitine palmitoyltransferase-1A (Cpt1a) and citrate synthase (Cs), and decreased the mRNA expression of inflammatory marker serum amyloid A 3 (Saa3) in the adipose tissues of diabetic mice. The results suggest that LC-MUFAs may ameliorate obesity-related metabolic dysfunction partly through increased expression of Pparg as well as its target genes, and decreased inflammatory marker expression in white adipose tissue.
Appendix
Available only for authorised users
Literature
1.
Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature. 2001, 414: 782-787. 10.1038/414782a.CrossRef
2.
King H, Aubert RE, Herman WH: Global burden of diabetes 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21: 1414-1431. 10.2337/diacare.21.9.1414.CrossRef
3.
Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ: Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001, 24: 1936-1940. 10.2337/diacare.24.11.1936.CrossRef
4.
Cheng D: Prevalence, predisposition and prevention of type II diabetes. Nutr Metab. 2005, 2: 29-10.1186/1743-7075-2-29.CrossRef
5.
Hulbert AJ, Turner N, Storlien LH, Else PL: Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc. 2005, 80: 155-169. 10.1017/S1464793104006578.CrossRef
6.
Abete I, Goyenechea E, Zulet MA, Martínez JA: Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc. 2011, Suppl 2: B1-B15.CrossRef
7.
Bergouignan A, Momken I, Schoeller DA, Simon C, Blanc S: Metabolic fate of saturated and monounsaturated dietary fats: the Mediterranean diet revisited from epidemiological evidence to cellular mechanisms. Prog Lipid Res. 2009, 48: 128-147. 10.1016/j.plipres.2009.02.004.CrossRef
8.
Gillingham LG, Harris-Janz S, Jones PJ: Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011, 46: 209-228. 10.1007/s11745-010-3524-y.CrossRef
9.
Kien CL: Dietary interventions for metabolic syndrome: role of modifying dietary fats. Curr Diab Rep. 2009, 9: 43-50. 10.1007/s11892-009-0009-6.CrossRef
10.
Matthan NR, Dillard A, Lecker JL, Ip B, Lichtenstein AH: Effects of dietary palmitoleic acid on plasma lipoprotein profile and aortic cholesterol accumulation are similar to those of other unsaturated fatty acids in the F1B golden Syrian hamster. J Nutr. 2009, 139: 215-221.CrossRef
11.
Bang HO, Dyerberg J, Sinclair HM: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr. 1980, 33: 2657-2661.
12.
Dyerberg J, Bang HO, Hjorne N: Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975, 28: 958-966.
13.
Ota T, Takagi T, Kosaka S: Changes in lipids of young and adult saury cololabis saira (Pisces). Mar Ecol Prog Ser. 1980, 3: 11-17.CrossRef
14.
Pascal JC, Ackman RG: Long-chain monoethylenic alcohol and acid isomers in lipids of copepods and capelin. Chem Phys Lipids. 1976, 16: 219-223. 10.1016/0009-3084(76)90029-3.CrossRef
15.
Hardy R, Mackie P: Seasonal variation in some of the lipid components of sprats (Sprattus sprattus). J Sci Food Agric. 1969, 20: 193-198. 10.1002/jsfa.2740200401.CrossRef
16.
Ratnayake WN, Ackman RG: Fatty alcohols in capelin, herring and mackerel oils and muscle lipids: I fatty alcohol details linking dietary copepod fat with certain fish depot fats. Lipids. 1979, 14: 795-803. 10.1007/BF02533518.CrossRef
17.
Graeve M, Kattner G: Species-specific differences in intact wax esters of Calanus hyperboreus and C. finmarchicus from Fram Strait-Greenland Sea. Mar Chem. 1992, 39: 269-281. 10.1016/0304-4203(92)90013-Z.CrossRef
18.
Falk-Petersen S, Sargent JR, Tande KS: Lipid composition of zooplankton in relation to the sub-arctic food web. Polar Biol. 1987, 8: 115-120. 10.1007/BF00297065.CrossRef
19.
Yang ZH, Miyahara H, Takemura S, Hatanaka A: Dietary saury oil reduces hyperglycemia and hyperlipidemia in diabetic KKAy mice and in diet-induced obese C57BL/6 J mice by altering gene expression. Lipids. 2011, 46: 425-434. 10.1007/s11745-011-3553-1.CrossRef
20.
Yang ZH, Miyahara H, Takeo J, Hatanaka A, Katayama M: Pollock oil supplementation modulates hyperlipidemia and ameliorates hepatic steatosis in mice fed a high-fat diet. Lipids Health Dis. 2011, 10: 189-10.1186/1476-511X-10-189.CrossRef
21.
Yang ZH, Miyahara H, Mori T, Doisaki N, Hatanaka A: Beneficial effects of dietary fish-oil-derived monounsaturated fatty acids on metabolic syndrome risk factors and insulin resistance in mice. J Agric Food Chem. 2011, 59: 7482-7489. 10.1021/jf201496h.CrossRef
22.
Iwatsuka H, Shino A, Suzuoki Z: General survey of diabetic features of yellow KK mice. Endocrinol Jpn. 1970, 17: 23-35. 10.1507/endocrj1954.17.23.CrossRef
23.
Castle CK, Colca JR, Melchior GW: Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb. 1993, 13: 302-309. 10.1161/01.ATV.13.2.302.CrossRef
24.
Folch J, Lees M, Stanley GHS: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1956, 226: 497-509.
25.
Lepage G, Roy CC: Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986, 27: 114-120.
26.
Mooradian AD: Nat Dyslipidemia in type 2 diabetes mellitus. Clin Pract Endocrinol Metab. 2009, 5: 150-159. 10.1038/ncpendmet1066.CrossRef
27.
Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007, 120: S12-S18.CrossRef
28.
Choi K, Kim YB: Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med. 2010, 25: 119-129. 10.3904/kjim.2010.25.2.119.CrossRef
29.
Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990, 113: 909-915.CrossRef
30.
Vaag A, Henrikssen JE, Beck-Nielsen H: Decreased insulin activation of glycogen synthesis in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with NIDDM. J Clin Invest. 1992, 89: 782-788. 10.1172/JCI115656.CrossRef
31.
Heptulla RA, Tamborlane WV, Cavaghan M, Bronson M, Limb C, Ma YZ, Sherwin RS, Caprio S: Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity. Pediatr Res. 2000, 47: 628-633. 10.1203/00006450-200005000-00012.CrossRef
32.
Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J: Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care Suppl. 2008, 2: S262-S268.CrossRef
33.
Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996, 97: 2859-2865. 10.1172/JCI118742.CrossRef
34.
Delarue J, Magnan C: Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 2007, 10: 142-148. 10.1097/MCO.0b013e328042ba90.CrossRef
35.
Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH: Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006, 82: 280-284. 10.1136/pmj.2005.039032.CrossRef
36.
Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J, Grant AM: Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes–a systematic review. Diabetes Obes Metab. 2004, 6: 85-94. 10.1111/j.1462-8902.2004.00315.x.CrossRef
37.
Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008, 118: 2992-3002. 10.1172/JCI34260.CrossRef
38.
Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444: 860-867. 10.1038/nature05485.CrossRef
39.
Faust IM, Johnson PR, Stern JS, Hirsh J: Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol. 1978, 235: 279-286.
40.
Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME, Jennings SS, Davis S, Jaitly R, Sgro JA: Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology. 1989, 39: 1415-1422. 10.1212/WNL.39.11.1415.CrossRef
41.
Asano J, Suzuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, Murase M, Orii T: Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev. 1994, 16: 454-458. 10.1016/0387-7604(94)90007-8.CrossRef
42.
Borg K: Physiopathological effects of rapeseed oil: a review. Acta Med Scand Suppl. 1975, 585: 5-13.
43.
Morgan NG, Dhayal S: Unsaturated fatty acids as cytoprotective agents in the pancreatic beta-cell. Prostaglandins Leukot Essent Fatty Acids. 2010, 82: 231-236. 10.1016/j.plefa.2010.02.018.CrossRef
44.
Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS: Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008, 134: 933-944. 10.1016/j.cell.2008.07.048.CrossRef
45.
Lindgärde F, Vessby B, Ahrén B: Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. Am J Clin Nutr. 2006, 84: 1009-1013.
46.
Paillard F, Catheline D, Duff FL, Bouriel M, Deugnier Y, Pouchard M, Daubert JC, Legrand P: Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr Metab Cardiovasc Dis. 2008, 18: 436-440. 10.1016/j.numecd.2007.02.017.CrossRef
47.
Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002, 53: 409-435. 10.1146/annurev.med.53.082901.104018.CrossRef
48.
Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996, 12: 335-363. 10.1146/annurev.cellbio.12.1.335.CrossRef
49.
Tamori Y, Masugi J, Nishino N, Kasuga M: Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes. 2002, 51: 2045-2055. 10.2337/diabetes.51.7.2045.CrossRef
50.
Olefsky JM, Saltiel AR: PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab. 2000, 11: 362-368. 10.1016/S1043-2760(00)00306-4.CrossRef
51.
Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes. 1996, 45: 1661-1669. 10.2337/diabetes.45.12.1661.CrossRef
52.
Goldberg IJ, Eckel RH, Abumrad NA: Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res. 2009, 50: S86-S90.CrossRef
53.
Schaffer JE, Lodish HF: Expression cloning and characterization of a novel long chain faty acid transport protein. Cell. 1994, 79: 427-436. 10.1016/0092-8674(94)90252-6.CrossRef
54.
Mantzoros CS: Leptin in relation to the lipodystrophy-associated metabolic syndrome. Diabetes Metab J. 2012, 36: 181-189. 10.4093/dmj.2012.36.3.181.CrossRef
55.
Lee MJ, Wang Y, Ricci MR, Sullivan S, Russell CD, Fried SK: Acute and chronic regulation of leptin synthesis, storage, and secretion by insulin and dexamethasone in human adipose tissue. Am J Physiol Endocrinol Metab. 2007, 292: E858-E864.CrossRef
56.
Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 1996, 93: 5793-5796. 10.1073/pnas.93.12.5793.CrossRef
57.
Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96: 939-949. 10.1161/01.RES.0000163635.62927.34.CrossRef
58.
Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA: Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab. 2000, 279: E1039-E1044.
59.
Stephens FB, Constantin-Teodosiu D, Greenhaff PL: New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007, 581: 431-444. 10.1113/jphysiol.2006.125799.CrossRef
60.
Ortenblad N, Mogensen M, Petersen I, Højlund K, Levin K, Sahlin K, Beck-Nielsen H, Gaster M: Reduced insulin-mediated citrate synthase activity in cultured skeletal muscle cells from patients with type 2 diabetes: evidence for an intrinsic oxidative enzyme defect. Biochim Biophys Acta. 2005, 1741: 206-214. 10.1016/j.bbadis.2005.04.001.CrossRef
61.
Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD: Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes. 2001, 50: 123-130. 10.2337/diabetes.50.1.123.CrossRef
62.
Sebastián D, Herrero L, Serra D, Asins G, Hegardt FG: CPT I overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance. Am J Physiol Endocrinol Metab. 2007, 292: E677-E686.CrossRef
63.
Perdomo G, Commerford SR, Richard AM, Adams SH, Corkey BE, O'Doherty RM, Brown NF: Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem. 2004, 279: 27177-27186. 10.1074/jbc.M403566200.CrossRef
Metadata
Title
Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice
Authors
Zhi-Hong Yang
Hiroko Miyahara
Yusuke Iwasaki
Jiro Takeo
Masashi Katayama
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2013
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/1743-7075-10-16

Other articles of this Issue 1/2013

Nutrition & Metabolism 1/2013 Go to the issue

Review

Milk protein for improved metabolic health: a review of the evidence

Brief communication

Evaluation of the relationship between GPR43 and adiposity in human

Review

Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy

Research

Fasting substrate oxidation in relation to habitual dietary fat intake and insulin resistance in non-diabetic women: a case for metabolic flexibility?

Review

Mitochondrial-associated metabolic disorders: foundations, pathologies and recent progress

Research

ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits